Replies To: Plavix and Vyvanse

Verwon says

Thu, 16 Jul 2009 20:24:17 -0800

Since he is referring to platele studies in diabetic patients, please rest assured that he wasn't saying anything relevant to your questions.

Now, as to your questions, first of all YES, the stimulant drugs can be dangerous for those with heart conditions, for instance it is specifically warned about with Adderall, you can read these warnings here:

http://www.prescriptiondrug-info.com/drug_details.asp?title=Adderall&page=1002540&ad=true#Adverse_effects

You can also scroll up or down that page to read much more drug information.

To your next question, the answer is also YES, these stimulant medications can increase your irritability levels.

I suggest you consult with your doctor for other possible treatment options.

Is there anything else I can help you with?

jayjay124 says

Thu, 16 Jul 2009 03:07:42 -0800

Wow Thanks Tom, But what the hell did you just say. Would you mind putting that in Laymans Terms. Not trying to sound smart or funny, we all are not medical researchers. I would love to hear from you again.

tom says

Sun, 3 May 2009 04:04:02 -0800

The PLUTO-Diabetes study revealed substantial differences in the platelet-related effects of 1-month treatment with clopidogrel and ASA combination versus ASA alone in diabetic patients. Indeed, addition of clopidogrel to ASA significantly decreases various measures of platelet activity after 30 days of treatment. Importantly, this study provides confidence supporting previous work showing that treatment with clopidogrel on top of monotherapy with ASA indeed yielded additional antiplatelet activity in a clinical setting of diabetes mellitus because these data are consistent regardless of the method used for assessing biomarkers of platelet function. There is always some confusion when picking the right laboratory tool for platelet function testing. In our study, the additional antiplatelet properties of clopidogrel beyond those of ASA have been proven by conventional plasma optical aggregation, with the rapid cartridge-based bedside platelet analyzers (PFA-100 and Ultegra), and using whole blood flow cytometry techniques by measuring expression of multiple activation-dependent receptors located on the platelet surface. Considering the marked heterogeneity of platelet activity between and within groups, it was critical for this study to apply different tests to assess platelet function to ensure that we adequately evaluate the characteristics of activated platelets.